Table 3.
Serum Samples and NC1-Specific Autoantibodies from EBA Patients Induce a Dose-Dependent Dermal-Epidermal Separation in Cryosections of Human Skin
| EBA sera | NC1-specific antibody preparations* | ||||||
|---|---|---|---|---|---|---|---|
| Patient | Dilution | IIF titer† | DES (%)‡ | Patient | Dilution | IIF titer† | DES (%)‡ |
| EBA8 | 1:2 | 80 | 70 | EBA8 | 1:4 | 80 | 65 |
| 1:4 | 40 | 60 | 1:16 | 20 | 40 | ||
| 1:16 | 10 | 40 | 1:64 | 5 | 5 | ||
| 1:160 | 1 | 10 | 1:320 | 1 | 0 | ||
| EBA11 | 1:4 | 80 | 60 | EBA11 | 1:2 | 80 | 75 |
| 1:8 | 40 | 55 | 1:8 | 20 | 50 | ||
| 1:32 | 10 | 30 | 1:32 | 5 | 30 | ||
| 1:320 | 1 | 5 | 1:160 | 1 | 10 | ||
*Antibodies specific to NC1 were purified from the serum of two EBA patients by immunoaffinity column chromatography and incubated with cryosections of human skin followed by a 2-hour incubation with human leukocytes.
†Titer of antibodies by indirect IF microscopy on 1 mol/L NaCl-split human skin.
‡Length of DEJ with separation in relation to total length (percent).